Oncology Central

Thermo-responsive fibrinogen nanogels: a viable thermo-responsive drug delivery agent for breast cancer therapy?


Breast cancer is reported to be the most frequent cancer type in women worldwide, with approximately 1.7 million newly diagnosed cases reported in 2012. During their lifetime, approximately 12% of women in the USA will develop invasive breast cancer, the second leading cause of cancer death of women in the USA [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.